Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Pivotal Study Recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Study Active, not recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021

May 14, 2021

Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update

May 10, 2021

Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico

Apr 27, 2021

Cellectar to Participate at Upcoming Institutional Investor Conferences

Mar 11, 2021

Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates

Mar 9, 2021

Cellectar to Participate at Upcoming Institutional Investor Conferences

Mar 5, 2021

Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update

Mar 2, 2021

Cellectar to Present at BIO CEO & Investor Digital Conference

Feb 10, 2021

Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia

Jan 27, 2021

Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

Jan 12, 2021
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...30
    © 2023 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A